Top executive appointments at Boehringer and Bristol-Myers

1 October 2012

German family-owned drug major Boehringer Ingelheim says that Engelbert Tjeenk Willink, a member of the board of managing directors, has decided to leave the company at the end of 2012.

The shareholders have appointed Allan Hillgrove as new member of the board of managing directors. Mr Hillgrove, an Australian national, will assume responsibility for the board division marketing and sales prescription medicines from January 1, 2013. Mr Hillgrove has been part of the Group since 1982 and worked as Head of Established Markets since 2010.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company News Directory



Companies featured in this story

More ones to watch >






Company Spotlight



More Features in Pharmaceutical